A phase 1 clinical study investigate safety, dosimetry and distribution of 68Ga-RMX-VH in patients with primary or recurrent Glioblastoma Multiforme (GBM)
Latest Information Update: 25 Nov 2022
At a glance
- Drugs 68-Ga-RMX-VH (Primary)
- Indications Adenocarcinoma; Glioblastoma; Pancreatic cancer; Solid tumours
- Focus Diagnostic use
- Sponsors RadioMedix
- 15 Nov 2022 Status changed from planning to recruiting, according to a RadioMedix media release.
- 15 Nov 2022 According to a RadioMedix media release, the first patients successfully dosed in an exploratory Investigational New Drug (eIND) application to evaluate 68Ga-RMX-VH for the diagnostic of Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).
- 13 Jul 2021 New trial record